Immunitybio is trading at $8.54, down 4.37%, with no confirmed November 5 company announcement directly explaining the decline. - Third-quarter results were expected November 5; earnings and Anktiva sales uptake remained in focus, but coverage did not link anticipation to the drop. - On November 4, shares closed at $8.93, up 7.72%, after news that the first European patients received Anktiva plus BCG. - The supplied sector trend was positive and does not explain the morning decline.